After the widespread dengue across nationwide. Various medicinal centers have come forward to present vaccine options for a clinical trial at the WHO research center.
Amongst them, the most advanced and promising vaccine is the live recombinant tetravalent dengue vaccine.
It is under the process of diagnoses as a -dose series on a 0/6/12-month schedule in Phase III clinical studies.
The vaccine has been submitted for registration in several endemic countries.
The recent report states that analysis is being carried to check its efficiency. The vaccine safety is thoroughly undergoing tests. It is to check the disease burden, programmatic suitability, including dose scheduling, and cost-effectiveness.
Other candidates for the vaccine are also going through clinical tests. To finalize the most effective vaccine as soon as possible.
The main aim of the WHO research team is to collaborate with partners and develop dengue vaccine to
Identify knowledge gaps and research needs related to the development. Evaluation and implementation of the vaccine.
• Build scientific consensus and develop guidance on the evaluation
Develop guidance on vaccine implementation, including introduction strategies
IVR is part of the Dengue Vaccine Initiative (DVI). A collaborative effort of partners to ease the introduction of future dengue vaccines.
By April 2016 WHO promises to bring forth an effective and long-term dengue vaccine to eradicate dengue. Which is a raising concern today.